Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)
At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).
The Reimbursement Committee recommends that most of the medicines maintain their current reimbursement status. However, the Reimbursement Committee recommends that general conditional reimbursement for certain types of nitrates should be eliminated as well as general reimbursement for adrenaline ampoules.
The Reimbursement Committee’s recommendation of 29 June 2011 is available via the box to the right (in Danish only).
On 4 July 2011, the Danish Medicines Agency launched a consultation with the companies whose medicines are comprised by the Committee’s recommendations. A copy of the Danish Medicines Agency’s letter can also be found to the right (in Danish only).
The consultation is open until 4 October 2011.
The relevant scientific societies and patient organisations as well as the Danish National Board of Health and the Institute for Rational Pharmacotherapy will be consulted concurrently, please see the list to the right (in Danish only).